A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer
Interventions: DRUG: SBT6050|DRUG: trastuzumab deruxtecan|DRUG: tucatinib|DRUG: trastuzumab|DRUG: capecitabine|DRUG: trastuzumab deruxtecan
Sponsor: Silverback Therapeutics